Standard BioTools (LAB) is One of the Best Life Sciences Penny Stocks, Here is Why

Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy.

As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock received 2 Hold ratings from analysts, with a projected median 1-year price target of $1.35. This yields an impressive upside potential of more than 52%.

Likoper/Shutterstock.com

On March 16, Ark Invest revealed changes to some of its existing holdings, including reductions across some of the smaller genomics stocks. The investment management firm exited some portion of its Standard BioTools Inc. (NASDAQ:LAB) holdings.

In late February, Michael Egholm, President & CEO, reflected on the company’s fourth quarter results. He described the passing year as a good one for the company, highlighting that the company was able to beat expectations through efficient processes being followed across the organization.

Egholm also noted that the company has been able to remain focused on efficiency due to the fact that it successfully implemented roughly $40 million worth of cost synergies during the year.

Standard BioTools Inc. (NASDAQ:LAB) is engaged in the production and sales of a variety of consumables, instruments, and services to help scientists and biomedical researchers create medical treatments. The company offers a technological platform that includes CyTOF, Hyperion, and Biomark X9. These platforms are used for advanced molecular and proteomics analysis.

While we acknowledge the risk and potential of LAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LAB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.